Hainan Poly Pharm Co Ltd - Asset Resilience Ratio

Latest as of June 2023: 2.33%

Hainan Poly Pharm Co Ltd (300630) has an Asset Resilience Ratio of 2.33% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 300630 total debt and obligations for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥146.93 Million
≈ $21.50 Million USD Cash + Short-term Investments

Total Assets

CN¥6.30 Billion
≈ $921.84 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2020–2022)

This chart shows how Hainan Poly Pharm Co Ltd's Asset Resilience Ratio has changed over time. See free cash flow generation of Hainan Poly Pharm Co Ltd to measure how efficiently the company converts operating cash flow to free cash.

Liquid Assets Composition Over Time

This chart breaks down Hainan Poly Pharm Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Hainan Poly Pharm Co Ltd assets under control.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥146.93 Million 2.33%
Total Liquid Assets CN¥146.93 Million 2.33%

Asset Resilience Insights

  • Limited Liquidity: Hainan Poly Pharm Co Ltd maintains only 2.33% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Hainan Poly Pharm Co Ltd Industry Peers by Asset Resilience Ratio

Compare Hainan Poly Pharm Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Curaleaf Holdings Inc.
TO:CURA
Drug Manufacturers - Specialty & Generic 3.73%
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723
Drug Manufacturers - Specialty & Generic 1.01%
Cronos Group Inc
TO:CRON
Drug Manufacturers - Specialty & Generic 69.94%
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
Drug Manufacturers - Specialty & Generic 18.70%
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799
Drug Manufacturers - Specialty & Generic 0.40%
Hunan Er Kang Pharmaceutical
SHE:300267
Drug Manufacturers - Specialty & Generic 1.19%
Sunflower Pharmaceuticals Group Co Ltd
SHE:002737
Drug Manufacturers - Specialty & Generic 22.45%
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
SHG:688505
Drug Manufacturers - Specialty & Generic 11.06%

Annual Asset Resilience Ratio for Hainan Poly Pharm Co Ltd (2020–2022)

The table below shows the annual Asset Resilience Ratio data for Hainan Poly Pharm Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2022-12-31 0.01% CN¥455.91K
≈ $66.71K
CN¥5.96 Billion
≈ $871.99 Million
-1.51pp
2021-12-31 1.51% CN¥70.55 Million
≈ $10.32 Million
CN¥4.66 Billion
≈ $682.23 Million
+1.50pp
2020-12-31 0.02% CN¥550.35K
≈ $80.53K
CN¥3.06 Billion
≈ $447.19 Million
--
pp = percentage points

About Hainan Poly Pharm Co Ltd

SHE:300630 China Drug Manufacturers - Specialty & Generic
Market Cap
$73.10 Million
CN¥499.57 Million CNY
Market Cap Rank
#20469 Global
#4684 in China
Share Price
CN¥0.89
Change (1 day)
+0.00%
52-Week Range
CN¥0.89 - CN¥0.89
All Time High
CN¥70.54
About

Hainan Poly Pharm. Co., Ltd. engages in research, development, production, and sale of pharmaceutical drugs in China and internationally. The company's dosage formulations comprise of tablets, capsules, granules, ointments, eye drops, pre-infusion, injection, lyophilization, and oral solutions. It also offers pharmaceutical preparations, active pharmaceutical ingredients, other raw materials, exc… Read more